RT Journal Article
T1 European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
A1 Garbe, Claus
A1 Amaral, Teresa
A1 Peris, Ketty
A1 Hauschild, Axel
A1 Arenberger, Petr
A1 Bastholt, Lars
A1 Bataille, Veronique
A1 Del Marmol, Veronique
A1 Dréno, Brigitte
A1 Fargnoli, Maria Concetta
A1 Grob, Jean-Jacques
A1 Höller, Christoph
A1 Kaufmann, Roland
A1 Lallas, Aimilios
A1 Lebbé, Celeste
A1 Malvehy, Josep
A1 Middleton, Mark
A1 Moreno-Ramirez, David
A1 Pellacani, Giovanni
A1 Saiag, Philippe
A1 Stratigos, Alexander J
A1 Vieira, Ricardo
A1 Zalaudek, Iris
A1 Eggermont, Alexander M M
A1 European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
K1 AJCC classification
K1 Confocal reflectance microscopy
K1 Cutaneous melanoma
K1 Dermatoscopy
K1 Follow-up examinations
K1 Imaging diagnostics
K1 Mutation testing
K1 Primary diagnosis
K1 Sequential digital dermatoscopy
K1 Total body photography
AB Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
YR 2020
FD 2020-01-09
LK http://hdl.handle.net/10668/14947
UL http://hdl.handle.net/10668/14947
LA en
DS RISalud
RD Apr 17, 2025